Associated Papers
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
41484121 (PubMed )
Supplement: 41467_2025_68076_MOESM1_ESM.pdf
Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights.
Anaya YA et al.
International Journal of Molecular Sciences, 2025
Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.
Ambrosini-Spaltro A et al.
Current Oncology (toronto, Ont.), 2023
BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors.
Talloa D et al.
Cancers, 2022
Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks.
Śmiech M et al.
Genes, 2020
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M et al.
Oncogene, 2018
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Leonetti A et al.
Cancer Treatment Reviews, 2018
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Caparica R et al.
Critical Reviews in Oncology/hematology, 2016
Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.
Millis SZ et al.
Clinical Genitourinary Cancer, 2015
Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.
Legrier ME et al.
Cancer Research, 2007
Select a paper to view details